Citations

Clear

6273 citation(s) found for "To, Andrew".

DUSP22 AND TP63 REARRANGEMENTS PREDICT OUTCOME OF ALK‐NEGATIVE ANAPLASTIC LARGE CELL LYMPHOMA: A DANISH COHORT STUDY
Dutoit, S.H., Bendix, Knud , Bedroske, Patrick P., Luoma, Ivy, Sattler, Cornelia, Bennani-Baiti, Nabila, Noergaard, Peter, Moeller, Michael, d’Amore, Francesco, Pedersen, Martin Bjerregård , Dutoit, S.H., Ketterling, Rhett P. , Steiniche, Torben , Feldman, Andrew L.

Mayo Clinic

Hematological Oncology | June 7, 2017 | Volume: 35 | Issue: S2 | Pages: 391-392

10.1002/hon.2439_157 Get It

HOST GENETIC VARIATION IN THE TNF AND NF‐ĸB PATHWAYS AND PROGNOSIS IN MANTLE CELL LYMPHOMA: AN ANALYSIS OF 2 STUDIES
Wang, Y., Wang, S.S., Inwards, David J. , Rothman, Nathaniel , Wang, Yucai , Habermann, Thomas M. , Maurer, Matthew J. , Link, Brian K. , Feldman, Andrew L. , Witzig, Thomas E. , Cozen, Wendy , Morton, Lindsay M. , Chanock, Stephen Jacob , Slager, Susan L. , Cerhan, James R.

Mayo Clinic

Hematological Oncology | June 7, 2017 | Volume: 35 | Issue: S2 | Pages: 151-152

10.1002/hon.2438_4 Get It

PROGNOSTIC FACTORS AND IMPACT OF ETOPOSIDE IN ADULTS WITH SYSTEMIC ALK‐POSITIVE ANAPLASTIC LARGE‐CELL LYMPHOMA: A POOLED ANALYSIS OF SIX STUDIES
Nguyen, Dinh-Phong , Schmitz, Norbert , Lamant, Laurence , Weisenburger, Dennis D. , Ziepert, Marita , Bast, M., Tilly, H., Jaïs, Jean Philippe, Sibon, David , Suzuki, Ritsuro , Feldman, Andrew L. , Gressin, Rémy , Nakamura, Shôji , Maurer, Matthew J. , Armitage, Jamés O. , Vose, Julie M. , Savage, Kerry J.

Mayo Clinic

Hematological Oncology | June 7, 2017 | Volume: 35 | Issue: S2 | Pages: 240-240

10.1002/hon.2438_103 Get It

THE 23‐GENE GENE EXPRESSION‐BASED ASSAY DOES NOT PREDICT INTERIM PET SCAN RESULTS AFTER ABVD IN ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA IN THE US INTERGROUP S0816 TRIAL
Li, H., Harvey, Yasmin , Chan, Fong Chun , Boyle, M., Straus, David J. , Sweetenham, John , Fanale, Michelle A. , Cook, James R. , Leonard, John P. , Friedberg, Jonathan W. , Gascoyne, Randy D. , Scott, David W. , Mottok, Anja , Evens, Andrew M. , Schöder, Heiko , Bartlett, Nancy L. , Barr, Paul M. , Hsi, Eric D. , Kahl, Brad S. , LeBlanc, Michael , Steidl, Christian , Rimsza, Lisa M. , Press, Oliver W.

Mayo Clinic

Hematological Oncology | June 7, 2017 | Volume: 35 | Issue: S2 | Pages: 92-93

10.1002/hon.2437_81 Get It

TARGETABLE FUSIONS OF THE FRK TYROSINE KINASE IN ALK‐NEGATIVE ANAPLASTIC LARGE CELL LYMPHOMA
Boddicker, Rebecca L., Dasari, Surendra , Asmann, Yan W. , Knudson, Ryan A., Eckloff, Bruce W., Jen, Jin , Hu, Gangqing , Greipp, Patricia T. , Link, Brian K. , Bennani, N. Nora , Cerhan, James R. , Feldman, Andrew L.

Mayo Clinic

Hematological Oncology | June 7, 2017 | Volume: 35 | Issue: S2 | Pages: 59-59

10.1002/hon.2437_45 Get It

CAUSE OF DEATH IN FOLLICULAR LYMPHOMA IN THE RITUXIMAB ERA: A POOLED ANALYSIS OF FRENCH AND US COHORTS
Ghesquières, Hervé , Nicolas‐Virelizier, Emmanuelle , Thompson, C., Traverse‐Glehen, Alexandra , Allmer, Cristine, Ansell, Steven M., Sarkozy, Clémentine , Link, Brian K. , Maurer, Matthew J. , Feldman, Andrew L. , Slager, Susan L. , Habermann, Thomas M. , Bachy, Emmanuel , Cerhan, James R. , Salles, Gilles

Mayo Clinic

Hematological Oncology | June 7, 2017 | Volume: 35 | Issue: S2 | Pages: 34-35

10.1002/hon.2437_15 Get It

Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma
Kondrashova, Olga , Nguyen, Minh , Shield‐Artin, Kristy , Tinker, Anna V. , Teng, Nelson N.H., Harrell, Maria I., Barker, Holly E. , Prakash, Rohit , Kass, Elizabeth M. , Sullivan, Meghan R. , Brunette, Gregory J. , Bernstein, Kara A. , Floquet, Anne , Friedländer, Michael , O’Malley, David M. , Oza, Amit M. , Robillard, Liliane, Maloney, Lara , Bowtell, David D.L. , Giordano, Heidi, Wakefield, Matthew J. , Simmons, Andrew D. , Harding, Thomas C., Raponi, Mitch , McNeish, Iain A. , Swisher, Elizabeth M. , Scott, Clare L. , Lin, Kevin K. , Kaufmann, Scott H. , Kuiper, Michael J. , Ho, Gwo‐Yaw , Jasin, Maria , Sullivan, Meghan R. , Coleman, Robert L. , Kichenadasse, Ganessan , Sun, James X. , Lin, Kevin , McNeish, Iain A , Swisher, Elizabeth M , Friedlander, Michael , Wakefield, Matthew J , Scott, Clare L , Bernstein, Kara A , Kondrashova, Olga , Bowtell, David D , Barker, Holly E , O'Malley, David M

Mayo Clinic

Cancer Discovery | June 6, 2017 | Volume: 7 | Issue: 9 | Pages: 984-998

10.1158/2159-8290.cd-17-0419 | PMID 28588062 Get It

Abstract High-grade epithelial ovarian carcinomas containing mutated BRCA1 or BRCA2 (BRCA1/2) homologous recombination (HR) genes are sensitive to platinum-based chemotherapy and PARP inhibitors (PARPi), while restoration of HR function due to secondary mutations in BRCA1/2 has been recognized as an important resistance mechanism. We sequenced core HR pathway genes in 12 pairs of pretreatment and postprogression tumor biopsy samples collected from patients in ARIEL2 Part 1, a phase II study of the PARPi rucaparib as treatment for platinum-sensitive, relapsed ovarian carcinoma. In 6 of 12 pretreatment biopsies, a truncation mutation in BRCA1, RAD51C, or RAD51D was identified. In five of six paired postprogression biopsies, one or more secondary mutations restored the open reading frame. Four distinct secondary mutations and spatial heterogeneity were observed for RAD51C. In vitro complementation assays and a patient-derived xenograft, as well as predictive molecular modeling, confirmed that resistance to rucaparib was associated with secondary mutations. Significance: Analyses of primary and secondary mutations in RAD51C and RAD51D provide evidence for these primary mutations in conferring PARPi sensitivity and secondary mutations as a mechanism of acquired PARPi resistance. PARPi resistance due to secondary mutations underpins the need for early delivery of PARPi therapy and for combination strategies. Cancer Discov; 7(9); 984–98. ©2017 AACR. See related commentary by Domchek, p. 937. See related article by Quigley et al., p. 999. See related article by Goodall et al., p. 1006. This article is highlighted in the In This Issue feature, p. 920
Holmium Laser Enucleation of the Prostate After Prostatic Urethral Lift Surgery: Feasibility and Technical Considerations from a Multi-Institutional Case Series
McAdams, Sean , Funk, Joel, Navetta, Andrew , Tayeb, Marawan M. El , Humphreys, Mitchell R.

Mayo Clinic

Journal of Endourology | June 6, 2017 | Volume: 31 | Issue: 8 | Pages: 774-779

10.1089/end.2017.0224 | PMID 28586247 Get It